Histone deacetylase inhibitor: Antineoplastic agent and radiation modulator

Advances in Experimental Medicine and Biology

Volumn 720, Issue , 2011, Pages 171-179

  Konsoula, Zacharoula ^a   Velena, Alfredo ^a   Lee, Rachel ^a   Dritschilo, Anatoly ^a   Jung, Mira ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; ABEXINOSTAT; ACETAMIDE DERIVATIVE; BIOLOGICAL MARKER; BUTYRIC ACID; DACINOSTAT; DEPSIPEPTIDE; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; M CARBOXYCINNAMIC ACID BIS HYDROXAMIDE; MERCAPTOACETAMIDE DERIVATIVE; MOCETINOSTAT; OXAMFLATIN; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; ROMIDEPSIN; TACEDINALINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT; RADIOPROTECTIVE AGENT; RADIOSENSITIZING AGENT;

ANTINEOPLASTIC ACTIVITY; BONE MARROW DISEASE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CELL CYCLE REGULATION; CONFERENCE PAPER; CONVALESCENCE; CUTANEOUS T CELL LYMPHOMA; DNA REPAIR; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIATION INJURY; RADIATION PROTECTION; RADIATION SICKNESS; RADIOSENSITIZATION; SURVIVAL RATE; ARTICLE; CELL PROTECTION; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; DRUG CLASSIFICATION; DRUG MECHANISM; ANIMAL; DNA DAMAGE; GENETIC EPIGENESIS; RADIATION DOSE; REVIEW;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA DAMAGE; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; RADIATION TOLERANCE; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS;

EID: 80053902712     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0254-1_14     Document Type: Conference Paper

References (47)

1. Struhl K, Moqtaderi Z (1998) The TAFs in the HAT. Cell 94:1-4 (Pubitemid 28347461)
2. Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389:349-352 (Pubitemid 27415209)
3. Katan-Khaykovich Y, Struhl K (2002) Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. Genes Dev 16:743-752 (Pubitemid 34274043)
4. Kouzarides T (1999) Histone acetylases and deacetylases in cell proliferation. Curr Opinion Genet Dev 9:40-48 (Pubitemid 29080385)
5. De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737-749 (Pubitemid 36399066)
6. Kurdistani SK, Grunstein M (2003) Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 4:276-284 (Pubitemid 36383954)
7. Fischle W, Kiermer V, Dequiedt F, Verdin E (2001) The emerging role of class II histone deacetylases. Biochem Cell Biol 79:337-348 (Pubitemid 32751926)
8. Verdin E, Dequiedt F, Kasler H (2003) Class II histone deacetylases: versatile regulators. Trends Genet 5:286-293 (Pubitemid 36507011)
9. Michan S, Sinclair D (2007) Sirtulins in mammals: insight into their biological function. Biochem J 404:1-13 (Pubitemid 46788079)
10. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. JMC 338:17-31 (Pubitemid 38429783)
11. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202 (Pubitemid 33741894)
12. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468
13. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T cell lymphoma. Oncologist 12:1247-1252 (Pubitemid 350106355)
14. Jung M, Velena A, Chen B, Petukhov PA, Kozikowski AP, Dritschilo A (2005) Novel HDAC inhibitors with radiosensitizing properties. Radiat Res 163:488-493 (Pubitemid 41490644)
15. Chen B, Petukhov PA, Jung M, Velena A, Eliseeva E, Dritschilo A, Kozikowski AP (2005) Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorg Med Chem Let 15: 1389-1392 (Pubitemid 40268998)
16. Konsoula Z, Cao H, Velena A, Jung M (2009) Pharmacokinetics- pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors. Mol Cancer Ther 8:2844-2851
17. Jung M, Yong KJ, Velena A, Lee SA (2009) Epigenetic Targets in drug discovery: cell-based assays for HDAC inhibitor hit validation. The Wiley-VCH series "Methods and Principles in Medicinal Chemistry" 42:119-137
18. Yu X, Guo ZS, Marcu MG et al (2002) Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94:504-513 (Pubitemid 34411289)
19. Kramer OH, Zhu P, Ostendorff HP et al (2003) the histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDA2. EMBO J 22:3411-3420 (Pubitemid 36834871)
20. Biade S, Stobbe CC, Boyd JT, Chapman JD (2001) Chemical agents that promote chromatin compaction radiosensitize tumor cells. Int J Radiat Biol 77: 1033-1042 (Pubitemid 32977932)
21. Karagiannis TC, El-Osta A (2006) Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25:3885-3893 (Pubitemid 43990743)
22. Arundel CM, Glicksman AS, Leith JT (1985) Enhancement of radiation injury in human colon tumor cells by the maturational agent Sodium Butyrate (NaB). Radiation Res 104:443-448 (Pubitemid 16146490)
23. Kim JH, Shin JH, Kim IH (2004) Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 59:1174-1180 (Pubitemid 38834312)
24. Zhang Y, Jung M, Dritschilo A, Jung M (2004) Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161:667-674 (Pubitemid 39149575)
25. Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ (2003) Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. JCB 160:1017-1027 (Pubitemid 36443871)
26. Bhaskara S, Chyla BJ, Amann JM, Knutson SK et al (2008) Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 30:61-72 (Pubitemid 351470157)
27. Miller KM, Tjeertes JV, Coates J, Legube G et al (2010) Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 17: 1144-1152
28. Kim GD, Choi YH, Dimtchev A, Jeong SJ, Dritschilo A, Jung M (1999) Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J Biol Chem 274:31127-31130
29. Ju R, Muller MT (2003) Histone deacetylase inhibitors activate p21 (WAF1) expression via ATM. Cancer Res 63:2891-2897 (Pubitemid 36667161)
30. Peterson CL, Cote J (2004) Cellular machineries for chromosomal DNA repair. Genes Dev 18:602-616 (Pubitemid 38489929)
31. Zhang Y, Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M (2007) Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 168:115-124 (Pubitemid 351292932)
32. Goodarzi AA, Noon AT, Deckbar D, Ziv Y, Shiloh Y, Lo brich M, Jeggo PA (2008) ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol Cell 31:167-177 (Pubitemid 352001394)
33. Groth A, Rocha W, Verreault A, Almouzni G (2007) Chromatin challenges during DNA replication and repair. Cell 128:721-733 (Pubitemid 46273574)
34. Kouzarides T (2007) Chromatin modifcations and their function. Cell 128:693-705
35. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299 (Pubitemid 37361445)
36. Camphausen K, Scott T, Sproull M, Tofilon PJ (2004) Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 10:6066-6071 (Pubitemid 39302609)
37. Folkvord S, Ree AH, Furre T et al (2009) Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys 74:546-552
38. Lavin MF (2008) Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9:759-769
39. Keogh MC, Kim JA, Downey M, Fillingham J et al (2006) A phosphase complex that dephosphorylates gH2AX regulates DNA damage checkpoint recovery. Nature 439:497-501 (Pubitemid 43152843)
40. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, Pilch DR, Staudt DW, Lee A, Bonner RF, Bonner WM, Nusssenzwig A (2003) Histone H2Ax phoshporylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 5:675-679 (Pubitemid 36818091)
41. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK (2003) Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310: 529-536 (Pubitemid 37163696)
42. Chung YL, Wang AJ, Yao LF (2004) Antitumor histone deacetylase inhibitos suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther 3: 317-325
43. Paoluzzi L, Figg WD (2004) Histone deacetylase inhibitors are potent radiation protectants. Cancer Biol Ther 3:612-613 (Pubitemid 41351096)
44. Papeleu P, Vanhaecke T, Elaut G et al (2005) Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? Crit Rev Toxicol 35:363-378 (Pubitemid 40686619)
45. Ungerstedt JS, Sowa Y, Xu WS et al (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:673-678 (Pubitemid 40282724)
46. Chang BK, Timmerman RB (2007) Stereotactic body radiation therapy: a comprehensive review. Am J Clin Onc 30:637-644 (Pubitemid 350307190)
47. Timmerman R, McGarry R, Yiannoutsos C, Papiez L et al (2006) Excessive toxicity when treating central tumors in a Phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Onc 24:4833-4839 (Pubitemid 46630909)